KR20140010093A - 혼합 집단 중 표적 dna의 서열분석을 위한 키트 및 방법 - Google Patents
혼합 집단 중 표적 dna의 서열분석을 위한 키트 및 방법 Download PDFInfo
- Publication number
- KR20140010093A KR20140010093A KR1020137025264A KR20137025264A KR20140010093A KR 20140010093 A KR20140010093 A KR 20140010093A KR 1020137025264 A KR1020137025264 A KR 1020137025264A KR 20137025264 A KR20137025264 A KR 20137025264A KR 20140010093 A KR20140010093 A KR 20140010093A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- sequencing
- sequence
- strand
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 196
- 238000000034 method Methods 0.000 title claims abstract description 73
- 230000035772 mutation Effects 0.000 claims abstract description 50
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 16
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 191
- 102000039446 nucleic acids Human genes 0.000 claims description 179
- 108020004707 nucleic acids Proteins 0.000 claims description 179
- 230000000903 blocking effect Effects 0.000 claims description 128
- 108020004414 DNA Proteins 0.000 claims description 90
- 230000000295 complement effect Effects 0.000 claims description 53
- 239000011541 reaction mixture Substances 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 45
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 32
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 claims description 27
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 24
- 230000003321 amplification Effects 0.000 claims description 23
- 238000002844 melting Methods 0.000 claims description 12
- 230000008018 melting Effects 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 238000001712 DNA sequencing Methods 0.000 claims description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 9
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 9
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 108020004705 Codon Proteins 0.000 claims description 7
- 108060002716 Exonuclease Proteins 0.000 claims description 7
- 102000013165 exonuclease Human genes 0.000 claims description 7
- 239000000833 heterodimer Substances 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000000137 annealing Methods 0.000 claims description 5
- 238000012175 pyrosequencing Methods 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- 108091027305 Heteroduplex Proteins 0.000 claims 1
- 208000035177 MELAS Diseases 0.000 claims 1
- 238000012165 high-throughput sequencing Methods 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- 201000011510 cancer Diseases 0.000 abstract description 11
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 description 50
- 239000000523 sample Substances 0.000 description 36
- 238000004925 denaturation Methods 0.000 description 16
- 230000036425 denaturation Effects 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000701806 Human papillomavirus Species 0.000 description 10
- 102200055464 rs113488022 Human genes 0.000 description 8
- 102200006531 rs121913529 Human genes 0.000 description 8
- 102200006540 rs121913530 Human genes 0.000 description 8
- 206010069754 Acquired gene mutation Diseases 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 102200055537 rs121913355 Human genes 0.000 description 7
- 230000037439 somatic mutation Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000006443 lactic acidosis Diseases 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- -1 nucleotide triphosphates Chemical class 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229940122558 EGFR antagonist Drugs 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000341657 Human papillomavirus type 18 Species 0.000 description 1
- 241000701790 Human papillomavirus type 45 Species 0.000 description 1
- 241000701789 Human papillomavirus type 56 Species 0.000 description 1
- 241000403132 Human papillomavirus type 97 Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 108091061939 Selfish DNA Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007671 third-generation sequencing Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/173—Nucleic acid detection characterized by the use of physical, structural and functional properties staining/intercalating agent, e.g. ethidium bromide
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161447490P | 2011-02-28 | 2011-02-28 | |
| US61/447,490 | 2011-02-28 | ||
| US201161532887P | 2011-09-09 | 2011-09-09 | |
| US61/532,887 | 2011-09-09 | ||
| PCT/US2012/026938 WO2012118802A1 (en) | 2011-02-28 | 2012-02-28 | Kit and method for sequencing a target dna in a mixed population |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140010093A true KR20140010093A (ko) | 2014-01-23 |
Family
ID=45815993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137025264A Withdrawn KR20140010093A (ko) | 2011-02-28 | 2012-02-28 | 혼합 집단 중 표적 dna의 서열분석을 위한 키트 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120225421A1 (enExample) |
| EP (1) | EP2681332A1 (enExample) |
| JP (1) | JP2014507950A (enExample) |
| KR (1) | KR20140010093A (enExample) |
| CN (1) | CN103517993A (enExample) |
| AU (1) | AU2012223438A1 (enExample) |
| CA (1) | CA2828535A1 (enExample) |
| WO (1) | WO2012118802A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016003197A1 (ko) * | 2014-07-01 | 2016-01-07 | 주식회사 유진셀 | 핵산말단분해효소를 이용한 서열-특이적 핵산검출 방법 및 장치와 이에 사용되는 키트 |
| KR20170124589A (ko) * | 2015-03-06 | 2017-11-10 | 필러 바이오사이언시스 인코포레이티드 | 중첩 암플리콘의 선택적 증폭 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2665500T3 (es) | 2010-03-08 | 2018-04-26 | Dana-Farber Cancer Institute, Inc. | Enriquecimiento de una PCR por COLD completa con secuencia de bloqueo de referencia |
| EP2691541B1 (en) | 2011-03-31 | 2017-10-18 | Dana-Farber Cancer Institute, Inc. | Method for enriching in single-stranded mutant sequences from mixture of wild-type and mutant sequences |
| WO2014089797A1 (zh) * | 2012-12-13 | 2014-06-19 | 深圳华大基因科技服务有限公司 | 用于高通量测序的锁核酸修饰的dna片段 |
| US10913977B2 (en) | 2013-07-24 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to enable enrichment of minor DNA alleles by limiting denaturation time in PCR or simply enable enrichment of minor DNA alleles by limiting the denaturation time in PCR |
| JP2018518155A (ja) * | 2015-04-15 | 2018-07-12 | ザ ジェネラル ホスピタル コーポレイション | Ｌｎａベース突然変異体エンリッチメント次世代シーケンシングアッセイ |
| CN107849606A (zh) * | 2015-04-20 | 2018-03-27 | 尼欧基因组学实验室股份有限公司 | 提高下一代测序灵敏度的方法 |
| WO2017070339A1 (en) * | 2015-10-20 | 2017-04-27 | Richardson Katherine | Microfluidic device for enrichment of nucleic acid sequence alterations |
| US11371090B2 (en) | 2016-12-12 | 2022-06-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection |
| US11174511B2 (en) | 2017-07-24 | 2021-11-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture |
| CN109536594B (zh) * | 2017-09-20 | 2022-11-01 | 深圳华大智造科技股份有限公司 | 一种用于Small RNA的测序方法、测序试剂和应用 |
| EP3998338B1 (en) * | 2019-07-11 | 2024-04-24 | Tokyo University of Science Foundation | Method for amplifying nucleic acid using solid-phase carrier |
| CN113567404A (zh) * | 2021-06-11 | 2021-10-29 | 上海交通大学 | 一种分析肿瘤细胞耐药性的方法和试剂盒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2293238A (en) * | 1994-09-13 | 1996-03-20 | Inceltec Ltd | Primers for replication and/or amplification reactions |
| US5849497A (en) * | 1997-04-03 | 1998-12-15 | The Research Foundation Of State University Of New York | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker |
| FR2779154B1 (fr) * | 1998-05-27 | 2002-07-12 | Bio Merieux | Procede d'amplification d'au moins une sequence nucleotidique particuliere et amorces de mise en oeuvre |
| US6045993A (en) * | 1998-05-30 | 2000-04-04 | Visible Genetics Inc. | Method, reagent and kit for genotyping of human papillomavirus |
| DE10012540B4 (de) * | 2000-03-15 | 2004-09-23 | Vermicon Ag | Oligonukleotide und Verfahren zum spezifischen Nachweis von Mikroorganismen durch Polymerase-Kettenreaktion |
| JP2004520812A (ja) * | 2000-08-30 | 2004-07-15 | ハプロゲン・エルエルシー | 対立遺伝子を決定するための方法 |
| GB0406863D0 (en) * | 2004-03-26 | 2004-04-28 | Qiagen As | Nucleic acid sequencing |
| US8455190B2 (en) * | 2007-08-01 | 2013-06-04 | Dana-Farber Cancer Institute, Inc. | Enrichment of a target sequence |
| US8071338B2 (en) * | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| ES2359058B1 (es) * | 2009-07-02 | 2012-03-27 | Consejo Superior De Investigaciones Cient�?Ficas (Csic) | Quimera de adn polimerasa del fago ph1 29. |
| WO2011012534A1 (en) | 2009-07-29 | 2011-02-03 | Nerviano Medical Sciences S.R.L. | Plk inhibitor salts |
| ES2665500T3 (es) | 2010-03-08 | 2018-04-26 | Dana-Farber Cancer Institute, Inc. | Enriquecimiento de una PCR por COLD completa con secuencia de bloqueo de referencia |
-
2012
- 2012-02-28 US US13/407,274 patent/US20120225421A1/en not_active Abandoned
- 2012-02-28 JP JP2013556801A patent/JP2014507950A/ja active Pending
- 2012-02-28 CA CA2828535A patent/CA2828535A1/en not_active Abandoned
- 2012-02-28 CN CN201280020801.3A patent/CN103517993A/zh active Pending
- 2012-02-28 WO PCT/US2012/026938 patent/WO2012118802A1/en not_active Ceased
- 2012-02-28 KR KR1020137025264A patent/KR20140010093A/ko not_active Withdrawn
- 2012-02-28 EP EP12708466.3A patent/EP2681332A1/en not_active Withdrawn
- 2012-02-28 AU AU2012223438A patent/AU2012223438A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016003197A1 (ko) * | 2014-07-01 | 2016-01-07 | 주식회사 유진셀 | 핵산말단분해효소를 이용한 서열-특이적 핵산검출 방법 및 장치와 이에 사용되는 키트 |
| KR20170124589A (ko) * | 2015-03-06 | 2017-11-10 | 필러 바이오사이언시스 인코포레이티드 | 중첩 암플리콘의 선택적 증폭 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2681332A1 (en) | 2014-01-08 |
| US20120225421A1 (en) | 2012-09-06 |
| JP2014507950A (ja) | 2014-04-03 |
| CA2828535A1 (en) | 2012-09-07 |
| CN103517993A (zh) | 2014-01-15 |
| AU2012223438A1 (en) | 2013-09-26 |
| WO2012118802A1 (en) | 2012-09-07 |
| WO2012118802A9 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230392191A1 (en) | Selective degradation of wild-type dna and enrichment of mutant alleles using nuclease | |
| KR20140010093A (ko) | 혼합 집단 중 표적 dna의 서열분석을 위한 키트 및 방법 | |
| JP5531367B2 (ja) | 標的配列の濃縮 | |
| JP7384459B2 (ja) | ヌクレアーゼ協同ｐｃｒ原理に基づいて低存在比のｄｎａ突然変異を濃縮する検出技術システムおよび使用 | |
| US8679788B2 (en) | Methods for the detection of nucleic acid differences | |
| CN105331733B (zh) | Egfr基因的多态性检测用探针、扩增用引物及其应用 | |
| US9765390B2 (en) | Methods, compositions, and kits for rare allele detection | |
| EP3334834A1 (en) | Method of preparing cell free nucleic acid molecules by in situ amplification | |
| CN110964814B (zh) | 用于核酸序列变异检测的引物、组合物及方法 | |
| CN107034277A (zh) | 一种检测低丰度基因突变的方法 | |
| EP3494236B1 (en) | Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence | |
| US10351903B2 (en) | Allele amplification bias | |
| CN110541033A (zh) | Egfr基因突变检测用组合物及检测方法 | |
| EP3350347B1 (en) | Methods and materials for detection of mutations | |
| JP2003518951A (ja) | 多型核酸配列の同時増幅およびリアルタイム検出のための方法 | |
| CN110592215A (zh) | 检测核酸序列的组合物及检测方法 | |
| JP2025118633A (ja) | 高い特異度の標的核酸増幅方法及びこれを利用した標的核酸増幅用組成物 | |
| Botezatu et al. | DNA melting analysis: application of the “open tube” format for detection of mutant KRAS | |
| MX2015003386A (es) | Metodo para la deteccion de mutaciones de braf y pi3k. | |
| CN112695097B (zh) | 一种区分cyp2d7p和cyp2d8p的cyp2d6*10遗传多态性检测试剂盒 | |
| CN110964833B (zh) | 一种一管检测血浆游离dna中kras和braf基因突变的试剂盒 | |
| KR20220085748A (ko) | 유방암 유전자 돌연변이 초고감도 선택적 증폭 방법 및 이를 위한 조성물 | |
| WO2022202728A1 (ja) | プライマー対、塩基配列変異の判定方法及び塩基配列の変異判定用キット | |
| WO2022167794A1 (en) | Method for enriching nucleic acids | |
| JP2010246400A (ja) | 多型の識別方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130925 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |